2.0 DESCRIPTION
2.1 Pathology
is the medical science and specialty practice that deals with all
aspects of disease, but with special reference to the essential
nature, the causes, and development of abnormal conditions, as well
as the structural and functional changes that result from disease
processes.
2.2 The surgical pathology services include accession,
examination, and reporting for a specimen which is defined as tissue
that is submitted for individual and separate attention, requiring
individual examination and pathologic diagnosis. These codes require
gross and microscopic examination.
3.0 POLICY
3.1 Pathology
and laboratory services are covered except as indicated.
3.2 Surgical
pathology procedures, billed by a pathologist, are covered services.
3.3 If the
operating surgeon bills for surgical pathology procedures, they
will be denied as incidental, since the definitive (microscopic)
examination will be performed later, after fixation of the specimen,
by the pathologist who will bill separately.
3.4 Dermatologists
are qualified to perform surgical pathology services. Therefore,
if a dermatologist bills for both the surgical procedure (e.g.,
Current Procedural Terminology (CPT) procedure code 11100, skin
biopsy) as well as the surgical pathology, both procedures are covered
in full.
3.5 Human papillomavirus testing (CPT procedure
codes 87620 - 87622) is covered as a diagnostic test for the assessment
of women with Atypical Squamous Cells of Undetermined Significance
(ASCUS) detected during a Pap smear.
3.6 The Nuclear magnetic Resonance
(NMR) LipoProfile-2 test, used with the NMR Profiler (CPT procedure
codes 83701 and 83704) is proven and covered for the management
of lipoprotein disorders associated with cardiovascular disease.
3.8 AlloMap® for molecular testing
is proven for use in cardiac transplant rejection surveillance.
4.0 EXCLUSIONS
4.1 Autopsy
and postmortem (CPT procedure codes 88000 - 88099).
4.2 Sperm penetration
assay (hamster oocyte penetration test or the zona-free hamster
egg test) is excluded for Invitro Fertilization (IVF) (CPT procedure
code 89329).
4.3 In-vitro chemoresistance and chemosensitivity
assays (stem cell assay, differential staining cytoxicity assay
and thymidine incorporation assay) are unproven.
4.4 Hair analysis
to identify mineral deficiencies from the chemical composition of
hair is unproven. Hair analysis testing (CPT procedure code 96902)
may be reimbursed when necessary to determine lead poisoning.
4.5 Insemination
of oocytes (CPT procedure code 89268).
4.6 Extended culture of oocyte(s)
embryo(s) four to seven days (CPT procedure code 89272).
4.7 Assisted
oocyte fertilization, microtechnique; less than or equal to 10 oocytes
(CPT procedure code 89280). Assisted oocyte fertilization, microtechnique;
greater than 10 oocytes (CPT procedure code 89281).
4.8 Biopsy
oocyte polar body or embryo blastomere (CPT procedure code 89290).
Biopsy oocyte polar body or embryo blastomere; greater than four
embryos (CPT procedure code 89291).
4.9 Cryopreservation reproductive
tissue, testicular (CPT procedure code 89335).
4.10 Storage
(per year) embryo(s) (CPT procedure code 89342). Storage (per year)
sperm/semen (CPT procedure code 89343). Storage (per year) reproductive
tissue, testicular/ovarian (CPT procedure code 89344). Storage (per
year) oocyte (CPT procedure code 89346).
4.11 Thawing of cryopreserved,
embryo(s) (CPT procedure code 89352). Thawing of cryopreserved, sperm/semen,
each aliquot (CPT procedure code 89353). Thawing of cryopreserved,
reproductive tissue, testicular/ovarian (CPT procedure code 89354).
Thawing of cryopreserved, oocytes, each aliquot (CPT procedure code
89356).
4.12 Oncotype Dx (S3854) is not covered due to the
lack of U.S. Food and Drug Administration (FDA) status.
4.13 OVA1™ test for ovarian cancer.
4.14 The Pathwork® Tissue of Origin Test is unproven
to assist in identifying the origin of poorly differentiated, undifferentiated,
or metastatic tumors.
5.0 Effective
Date
s5.1 July 23,
2008, for NMR LipoProfile-2 test, used with the NMR Profiler.
5.2 February 19, 2015, for AlloMap®
molecular expression testing for cardiac transplant rejection surveillance.